Low methylthioadenosine phosphorylase expression is associated with worse survival in patients with acute myeloid leukaemia

Yiyu Xiao; Qianqian Peng; Advaith Maya Sanjeev Kumar; Houda Alachkar

doi:10.1002/ctm2.70015

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (9) : e70015 DOI: 10.1002/ctm2.70015

LETTER TO THE JOURNAL

Low methylthioadenosine phosphorylase expression is associated with worse survival in patients with acute myeloid leukaemia

Author information +

History +

PDF

Cite this article

Download citation ▾

Yiyu Xiao, Qianqian Peng, Advaith Maya Sanjeev Kumar, Houda Alachkar. Low methylthioadenosine phosphorylase expression is associated with worse survival in patients with acute myeloid leukaemia. Clinical and Translational Medicine, 2024, 14(9): e70015 DOI:10.1002/ctm2.70015

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Pegg AE, Williams-Ashman HG. On the role of S-adenosyl-L-methionine in the biosynthesis of spermidine by rat prostate. J Biol Chem. 1969; 244(4): 682-693.

[2]	Engstrom LD, Aranda R, Waters L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023; 13(11): 2412-2431.

[3]	de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023; 83(23): 3861-3867. Published online September 5, 2023.

[4]	Ceramil E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5): 401-404.

[5]	Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269): pl1.

[6]	Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22): 2059-2074.

[7]	Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022; 40(8): 850-864. e9. doi:10.1016/j.ccell.2022.07.002

[8]	Haferlach T, Kohlmann A, Basso G, et al. The clinical utility of microarray-based gene expression profiling in the diagnosis and sub-classification of leukemia: final report on 3252 cases from the International MILE Study Group. Blood. 2008; 112(11): 753.

[9]	Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6): 675-678.

[10]	Rondeau V, Culp-Hill R, O’Brien C, et al. Abstract NG07: targeting polyamines metabolism in acute myeloid leukemia stem cells. Cancer Res. 2023; 83(7_Supplement): NG07.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.